Table 2.
Different results on various suPAR studies in FSGS and other glomerulopathies.
Negative results | References | Positive results | References |
---|---|---|---|
Serum suPAR levels did not correlate to eGFR | [9, 13] | Serum suPAR levels were inversely correlated with eGFR | [10, 14–24] |
Serum suPAR levels did not correlate to CRP levels | [10, 13, 17] | Serum suPAR levels were positively correlated with CRP levels | [16, 18] |
Serum suPAR levels are not influenced by immunosuppression | [17, 18] | Serum suPAR levels are influenced by immunosuppression | [10, 93] |
Serum suPAR levels are not influenced by subtypes of FSGS | [11, 13, 89] | Serum suPAR levels are influenced by subtypes of FSGS | [12] |
Urine suPAR levels are influenced by subtypes of FSGS | [67] | ||
Serum suPAR levels are not different between primary and secondary FSGS | [12] | Serum suPAR levels are higher in primary FSGS than in secondary FSGS | [89] |
Urine suPAR levels are higher in primary FSGS than in secondary FSGS | [67] | ||
Serum suPAR levels did not predict response to steroids | [14, 18] | High serum suPAR levels predicted better response to steroids | [13] |
High serum suPAR levels were not associated with acute tubulointerstitial lesions | [13] | High serum suPAR levels were associated with >50% interstitial fibrosis | [12] |
suPAR, soluble urokinase-type plasminogen activator receptor; FSGS, focal segmental glomerulosclerosis; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate.